Comparison between SS and NGS results. (A) Percentage of patients positive for mutations by SS and by NGS. Among patients positive for mutations by NGS, 31 (13.1%) had high-level mutations only (≥20%; detectable by SS too); 29 (12.3%) had both ≥1 high-level mutations and ≥1 low-level mutations (≤20%; detectable by NGS only); 51 (21.6%) had only low-level mutations. A low-level T315I was detected in 10 patients; 59 additional patients had ≥1 low-level mutations known to be associated with resistance to imatinib or 2GTKIs other than the T315I (ie, Y253H; E255K/V; V299L; F317L/V/I/C; F359V/I/C). The remaining 10 patients had only low-level mutations with an unknown resistance profile and/or not listed in the COSMIC database. (B) Patients positive for 1 or multiple mutations as assessed by SS vs NGS. BOS, bosutinib; DAS, dasatinib; IMA, imatinib; NIL, nilotinib; pts, patients; seq, sequencing.